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HUMAN BETA-DEFENSIN-2 CONTROLS CELL CYCLE 
IN MALIGNANT EPITHELIAL CELLS: IN VITRO STUDY
E. Zhuravel1*, T. Shestakova1, O. Efanova1, Yu. Yusefovich1, D. Lytvin2, M. Soldatkina1, P. Pogrebnoy1 
1R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv,Ukraine
2Institute of Food Biotechnology and Genomics,NAS of Ukraine, Kyiv, Ukraine
Aim: In the present research we analyze the mechanism of human beta-defensin-2 (hBD-2) influence on cultured malignant epithelial 
cell growth. Materials and Methods: The analysis of a concentration-dependent effect of recombinant hBD-2 (rec-hBD-2) on cell 
growth patterns and cell cycle distribution has been performed in vitro with 2 cell lines (human lung adenocarcinoma A549 cells and 
human epidermoid carcinoma A431 cells) using MTT test, flow cytometry and direct cell counting. To study intracellular localization 
of hBD-2 immunocytofluorescent and immunocytochemical analyses were applied, and effect of hBD-2 on signal cascades involved 
in cell cycle regulation has been studied by Western blotting. Results: According to our data, rec-hBD-2 exerts a concentration-
dependent effect on the viability of cultured A549 and A431 cells. It causes proproliferative effect at concentrations below 1 nM, 
significant suppression of cell proliferation at concentration range from 10 nM to 1 μM (p<0.05), and cell death at higher con-
centrations. Using flow cytometry we have demonstrated that hBD-2 dependent growth suppression is realized via cell cycle arrest 
at G1/S phase (p<0.05). Also, we have registered significant activation of pRB and decreased expression of Cyclin D1 in cells 
treated with the defensin compared to untreated control cells, while the expression of p53 remains unaffected. The study of intracel-
lular localization of hBD-2 in these cells has revealed that exogeneously added defensin molecules enter the cells, are distributed 
throughout the cytoplasm and could be detected in cell nuclei. The model study using A549 cells treated with 1,25-(OH)2D3 has 
shown similar cell growth suppression effect of native endogenously produced hBD-2. Conclusion: The results of our study suggest 
that in malignant epithelial cells hBD-2 may control cell growth via arrest of G1/S transition and activation of pRB.
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INTRODUCTION
Human beta-defensins (hBDs) belong to a family 
of antimicrobial peptides that constitute an important 
part of the innate immune defense system. hBDs are 
expressed mostly in epithelial tissues. Up to date, four 
hBDs, hBD-1–4 have been identified in human tissues. 
These molecules are small, with a molecular weight rang-
ing from 3.5 to 4.5 kDa, possess high positive net charge 
and hydrophobic properties that allow their interaction 
with microbial membrane, its penetration or its destruc-
tion. They exert direct antimicrobial action and are active 
against bacteria, fungi, viruses; in parallel, according 
to the recent data, they possess multiple biologic activi-
ties, in particular, immunomodulatory ones, and are 
implicated in anti-tumor response [reviewed in 1, 2]. 
Biophysical properties of defensin molecules allow 
them to form dimers or octamers in water solutions 
and to create pores in target membrane or disrupt/
penetrate the membranes causing lysis of bacterial 
and tumor cells [3, 4]. Interestingly, it has been docu-
mented that at lower concentrations defensins (at par-
ticular, alpha-defensins) may cause a concentration-
dependent effect on cultured eucaryotic cells leading 
to stimulation of cell proliferation [5–7]. Moreover, 
in vivo effects of antimicrobial peptides could be also 
of opposite character dependent on their concentra-
tions and patterns of tumor microenvironment [1]. 
In present research, we have studied the mechanism 
of growth suppressing action of human beta-defen-
sin-2 (hBD-2) in vitro. hBD-2, a 41 residue peptide, was 
originally isolated from extracts of lesional scales from 
psoriatic skin in 1997 [8]; its expression is characteristic 
for skin, respiratory tract and gastrointestinal epithe-
lium. hBD-2 expression is inducible upon treatment 
with bacterial products and some cytokines [9]. Simi-
larly to neutrophylic defensins, HNPs, this antimicrobial 
peptide has been shown to affect cell proliferation and 
viability in a concentration-dependent manner [10, 11].
In this work, we have shown that recombinant 
hBD-2 (rec-hBD-2) exogenously added into cell 
cultivation medium at a wide concentration range 
causes stimulation of cell proliferation in picomolar 
concentrations and a killing effect at concentrations 
higher than 100 nM; rec-hBD-2 at concentrations 
of 10–100 nM is capable to enter cells, it accumulates 
in cell nuclei and causes cell growth suppression via 
cell cycle arrest in G1/S phase and activation of pRB. 
MATERIALS AND METHODS
Cell lines and treatment with recombinant 
hBD-2 peptide. Human non-small cell lung ad-
enocarcinoma A549 cells were kindly provided 
by Dr. V. Kashuba (Karolinska Institute, Sweden) 
and human epidermoid carcinoma A431 cells were 
obtained from the Bank of Cell Lines from Human 
and Animal Tissues, R.E. Kavetsky Institute of Experi-
mental Pathology, Oncology and Radiobiology of NAS 
of Ukraine (Kyiv, Ukraine). The cells were cultured in vi-
tro in DMEM culture medium with high glucose content 
supplemented with 10% fetal bovine serum (FBS), 
100 units/ml penicillin G sodium, 100 μg/ml strepto-
mycin sulfate in 5% CO2 athmosphere at 37 ˚C.
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To study the effect of exogenous defensin on cell 
growth, we have used the preparation of rec-hBD-2 ex-
pressed in bacterial cells as GST-hBD-2 fusion protein 
purified by standard two-step procedure as described 
earlier [12]. Protein concentration was determined 
by the method of Bradford [13] and by UV absor-
bance at 280 nm using spectrophotometer Nano-
drop-1000 (USA). 
Cells were cultured for 24 h in serum-free me-
dium or (dependent on experimental conditions) 
in culture medium supplemented with 2.5% FBS, 
to nearly 50% confluence and then treated by ad-
dition of rec-hBD-2 at various concentrations (from 
10 pM to 100 M) for 48 h. After the treatment, cells 
were triply washed with PBS, detached with trypsin, 
and counted in hemocytometer or were subjected 
to flow cytometry analysis. The percent of dead cells 
was analized using tripan blue staining. Each experi-
ment was repeated in triplicate. 
For flow cytometry analysis, the attached cells 
were harvested by trypsinization, pelleted at 4 ˚C 
(500 g) for 5 min, washed twice in PBS, and resuspended 
in 1 ml of hypotonic lysis buffer (0.1% sodium citrate, 0.1% 
Triton X-100, 5 g/ml PI (Sigma, USA). The cells were in-
cubated at room temperaure for 30 min in the dark, and 
analyzed by Becton Dickinson FACS Calibur. The data 
were analyzed with the use of CellQuest software package 
and ModFit LT2.0 program (BDIS, USA) for Mac comput-
ers. All analyses were performed three times. 
To evaluate the effect of rec-hBD-2 on cell viability, 
MTT-test has been applied [14]. Shortly, A549 and 
A431 cells were seeded into 96-well plates and incu-
bated with rec-hBD-2 for 48 h in serum-free medium. 
Then the cells were treated with МТТ (3-[4,5-dimeth-
ylthiazole-2-yl]-2,5-diphenyltetrazolium bromide), 
and colorimetric reaction was evaluated with the use 
of ELISA reader (Awareness Technology Inc, USA) 
at the wave lengths min =545 and max=630.
In some experiments to study the effect of native 
endogenously produced hBD-2, A549 cells were 
treated with 40 ng/ml of 1,25-(OH)2D3 for 48 h. Then 
the attached cells were triply washed with PBS and 
counted in hemocytometer.
RT-PCR analysis of hBD-2 expression. Total 
RNA was isolated from tissue samples by the method 
of Chomzynski and Sacchi [15]. For detection of ex-
pression of hBD-2 mRNA in tissue samples, semiquan-
titative RT-PCR analysis was performed using specific 
primers (hBD-2 — F: -5'-gaagctcccagccatcagcc; R: — 
5'-gtcgcacgtctctgatgaggga; beta-actin — F: -5'-ctg-
gaacggtgaaggtgaca; R: 5'-aagggacttcttgtaacaatgca). 
The expression level of beta-actin (the house-keeping 
gene) served as a loading control. The products 
of RT-PCR were routinely analyzed by electrophoresis 
in agarose gel. The relative mRNA expression levels 
were analyzed using TotalLab Program.
Western-blot analysis. To analyse the level of ex-
pression and/or phosphorylation of different proteins, 
the cultured cells were treated with rec-hBD-2 for 
48 h as described above, and then washed with PBS and 
lyzed in PBS solution containing 50 mM Тris-НCl (pH 7.0), 
50 mM EDTA, 2% Triton Х-100. The concentration of total 
protein was determined by the method of Lowry.
The proteins were separated by electrophoresis 
in 9–22% gradient polyacrylamide gel and transferred 
to nitrocellulose membrane Hybond-ECL, RPN3032D 
(Amersham Biosciences, USA). Nonspecific binding 
sites were blocked with 1Х PBS-Т, 5% BSA solution for 
1 h, and the blots were incubated with primary Abs, 
and then with secondary polyclonal HRP-conjugated 
anti-rabbit IgG or anti-mouse IgG Abs (DakoCytoma-
tion, Denmark). The ECL Western blotting detection 
system (Amersham Pharmacia Biotech) was used 
to reveal immunoreactivity. For Western blot analysis, 
the following antibodies were used: anti-pRB-Abs, 
anti-p53-Abs, anti-CyclinD1-Abs (Cell Signaling Tech, 
USA) and MoAbs against beta-actine (Sigma, USA). 
All antibodies were used at the working dilutions ac-
cording to manufacturer instructions. 
Confocal microscopy and immunocytoche-
mistry. A431 and A549 cells were plated into 6 cm Petri 
dishes on glass cover slides. Control cells were grown 
in fresh growth media supplemented with 2.5% FBS, 
while experimental cells were additionally treated for 
48 h with 1 M rec-hBD-2. After the treatment, cells 
were washed in PBS and fixed for 1 h at -20 ˚ C in meth-
anol-acetone (1:1) solution. Cells were then washed 
three times with PBS and blocked with 5% normal goat 
serum (VectorLaboratories, Inc., Burlingame, CA) 
in PBS for 1 h at room temperature. Next, cells were 
incubated for 1 h with rabbit anti-hBD-2 polyclonal 
antibody (Santa-Cruz, USA) diluted 1:50 in blocking 
solution. Following this, cells were washed and incu-
bated for 1 h with goat anti-rabbit IgG-FITC antibody 
(Sigma F0382) at a dilution of 1:80. Finally, the cells 
were incubated with 0.5 μg/ml DAPI (4–6-diamidino-
2-phenylindole). Confocal images were obtained using 
a Zeiss LSM 510 META confocal microscope equipped 
with lasers for 405 nm and 488 nm excitation for DAPI 
and FITC, correspondingly. Images were collected 
with Plan-Apochromate 63X/1,4 Oil DIC lens (Zeiss, 
Germany) in multi-track mode using line switching with 
averaging of 16 readings. Excitation of FITC and DAPI 
was collected with LP 505 and LP 420 filters.
Also, to detect intracellular localization of recombi-
nant hBD-2, the cells were treated with 1 M hBD-2 for 
48 h, washed with PBS, fixed in cold methanol/acetone 
(1:1) mixture for 24 h at -20 °С, blocked with 5% nor-
mal goat serum for 1 h at RT. For immunocytochemi-
cal detection of hBD-2 staining we have used rabbit 
polyclonal anti-hBD-2 Abs (Santa-Cruz, USA) at the 
dilution 1:100. EnVision System and DAB (DAKO, 
Denmark) were used for visualization. The slides were 
analized using Axioplan microscope (Zeiss, Germany). 
On average, 10 fields were examined for each sample,
Statistical analysis. The data are reported as the 
mean±SD. The statistical significance of differences 
between mean values was assessed by the Stu-
dent’s t-test. Values p<0.05 were considered as sta-
tistically significant.
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RESULTS
Our research has been performed in vitro using 
rec-hBD-2 exogenously added to the cell culture me-
dium. Control experiment was carried out on the model 
of vitamin-D3-induced expression of native hBD-2. Re-
combinant hBD-2 was expressed in bacterial cells as GST-
hBD-2 fusion protein and purified by standard procedure 
as described earlier [13]. The purified defensin preparation 
was of 98% purity as justified by the data of electrophoretic 
analysis, WB, HPLC, and active in antimicrobial test against 
Pseudomonas aeruginosa (data not shown). 
The analysis of rec-hBD-2 effect on cell growth 
patterns in vitro. To study the effect of exogenous 
rec-hBD-2 on growth patterns of cultured A431 and 
A549 cells, the cells were treated with rec-hBD-2 that 
was added into serum-free culture medium at different 
concentrations (from 10 pM up to 100 M) for 48 h. Us-
ing MTT-analysis, we have revealed that hBD-2 caused 
a concentration-dependent effect on cell growth rates, 
in particular, it stimulated cell proliferation at concentra-
tion range from 10 pM to 1 nM, and significantly sup-
pressed cell growth at concentration from 10 nM to 1 M 
(Fig. 1). Treatment of both cell lines with recombinant 
defensin at concentrations higher than 1000 nM resulted 
in cell death. The data of MTT-test were supported by the 
results of direct cell counting (Fig. 2). These effects were 
hBD-2-specific as far as pretreatment of rec-hBD-2 with 
anti-hBD-2 Abs completely abolished the above men-
tioned effects (Fig. 2).
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Fig. 1. Exogenous rec-hBD-2 affects the number of viable 
cultured cells of A431 and A549 lines. Cells were cultured in 96-
well plates in serum free culture medium and treated with ex-
ogenously added recombinant hBD-2 at concentrations from 
10 pM to 100 M for 48 h.  The number of viable cells was evalu-
ated by MTT analysis. The data of three independent experiments 
are presented as the mean ± SD
Flow cytometry analysis. To explore the mecha-
nism implicated in the growth-inhibition effect 
of hBD-2 we have selected the hBD-2 concentration 
range of 10–1000 nM, and using flow cytometry analy-
sis we have analyzed the influence of rec-hBD-2 ex-
ogenously added into the cell culture medium on cell 
cycle distribution of cultured A549 and A431 cells after 
48 h incubation. Flow cytometry analysis of A431 cells 
treated with rec-hBD-2 has revealed (Fig. 3) a concen-
tration-dependent cell growth arrest at G1/S phase 
(p<0.05). Similar results were registered for A549 cells 
treated with rec-hBD-2 (data not shown). At the same 
time treatment of cells with 10–1000 nM of hBD-2 had 
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Fig. 2. A concentration-dependent effect of exogenous re-
combinant hBD-2 on the number of viable cultured A549 and 
A431cells. The number of attached cells was evaluated by direct 
cell counting. Cells were cultured in 96-well plates in serum free 
medium and treated with exogenously added rec-hBD-2 concen-
trations of 10, 100 nM and 1 M for 48 h. To analyze the specificity 
of growth-suppressing activity of rec-hBD-2, 50 ng of hBD-2 were 
pre-incubated for 1 h with 0.8 μg of anti-hBD-2 Abs (Santa-Cruz, 
USA), and then added to the cell incubation medium for 48 h. The 
data of four independent experiments are presented as the mean ± 
SD. *The difference is significant as compared to control (p < 0.05)
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Fig. 3. Flow cytometry analysis of cell cycle distribution of A431 cells 
treated or not treated with rec-hBD-2 for 48 h (a-e). Cells were 
cultured in 10 cm Petri dishes in culture medium  supplemented 
with 10% FBS to 50% confluency, then the medium was replaced 
by the one supplemented with 2.5% FBS, and the cells were treated 
by addition of  rec-hBD-2 for  48 h. After the treatment, the cells were 
triply washed with PBS, detached with trypsin and subjected to flow 
cytometry analysis as described in Materials and Methods section: 
a — the data of three independent experiments are presented as the 
mean ± SD; b — control A431 cells; c, d, e — the cells treated with 
10, 100, and 1000 nM rec-hBD-2 respectively
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no effect on cell mortality: the percent of apoptotic 
cells in control and hBD-2 treated A431 cells didn’t dif-
fer significantly and did not exceed 4%. There data 
were supported by the results of tripan blue staining.
The analysis of rec-hBD-2 effect on signal 
pathways involved in cell cycle regulation in vitro. 
To explore how rec-hBD-2 affects specific signal cas-
cades involved in cell cycle regulation in cultured cells, 
we have studied the state of some proteins which ac-
tivity is required for G1/S cell cycle transition. We have 
analyzed phosphorylation of pRB, expression levels 
of cyclin D1 and p53 in A549 and A431 cells treated with 
1 M rec-hBD-2 in comparison to control (untreated) 
cells. We have shown, rec-hBD-2 treatment resulted 
in the dramatic reduction of pRB phosphorylation, and 
significant decrease of cyclin D1 expression, while 
p53 expression remained unaffected (Fig. 4). So, one 
may conclude that G1/S cell cycle arrest in hBD-2 treat-
ed cells could be possibly realized via activation of pRB.
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Fig. 4. Western blot analysis of pRB phosphorylation and expres-
sion levels of cyclin D1 and p53 in A549 and A431 cells treated 
with 1 M rec-hBD-2 for 48 h. a: line 1 — intact A549 cells; line 
2 — A549 cells treated with 1 M rec-hBD-2; line 3 — intact 
A431 cells; line 4 — A431 cells treated with 1 M rec-hBD-2; 
b, c — graphic representations of Western blot analysis data 
counted with the use of GelPro 4.0 program
The study of intracellular localization of hBD-2. 
To analyze whether exogenously added rec-hBD-2 en-
ters the cell, two methods were used — immunocyto-
chemical analysis and immunocytofluorimetry. In both 
cases we have compared hBD-2-specific immunos-
taining in defensin-treated A431 and A549 cells versus 
intact control cells, and have detected hBD-2 specific 
immunostaining in the fist case. According to our re-
sults (Fig. 5), rec-hBD-2 enters the cells, is distrib-
uted in cytoplasm and is accumulated in cell nuclei 
of A431 cells (Fig. 5) and A549 cells (Fig. 7). 
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Fig. 5. Rec-hBD-2 is detected in cytoplasm (a) and nuclei (b, 
c) of hBD-2 treated A431 cells but not in control cells. Confocal 
microscopy was applied for analysis of immunofluorescent stain-
ing of hBD-2 in A431 cells treated (1–3) or not treated (4–6) with 
the recombinant defensin at the concentration of 1 M for 48 h. 
1, 4- staining with FITC-anti-hBD-2 Abs; 2, 5 — DAPI staining, 3, 
6 — overlay. c — evaluation of hBD-2 specific nuclear staining 
of A431 cells treated with  1 M rec-hBD-2
Modeling of action of native hBD-2 in vitro. To find 
out whether the data obtained with the use of recom-
binant defensin may reflect similar physiologic events 
related to the action of native hBD-2, we have designed 
an experiment on a model of A549 cells in which the 
hBD-2 mRNA expression is induced by treatment with 
metabolites of vitamin D3 (VD3). First of all, using RT-
PCR analysis we have determined that intact A549 cells 
do not express hBD-2 mRNA, while its expression 
in these cells could be induced if the cells are treated 
with 4·10–7 M 1,25-(0H)2D3 or 25(0H)D3 for 12 h (Fig. 6). 
Next, with the use of direct cell counting we have 
revealed that A549 cells incubated with metabolites 
of VD3 for 48 or 72 h demonstrated significantly 
suppressed cell proliferation rate compared with the 
control cells (by 1.3 and 1.6 fold respectively, p<0.05), 
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and that such growth suppression could be eliminated 
by the addition of anti-hBD-2 Abs into the cell culture 
medium. Next, using immunocytochemical and immu-
nofluorescent staining we have detected an appear-
ance of hBD-2-specific immunostaining in cytoplasm 
and nuclei of A549 cells treated with VD3 metabolites 
for 48–72 h (see Fig. 7). 
DISCUSSION
In our research we have received new data that 
allow to understand the possible mechanism of cell 
growth-suppressing activity of hBD-2 toward human 
cancer cells in vitro. As we have shown, rec-hBD-2 ex-
erts a concentration-dependent effect toward cultured 
cells of two different lines — lung adenocarcinoma 
A549 cells and vulval epidermoid carcinoma A431 cells. 
This defensin stimulates cell proliferation at the con-
centrations below 1 nM, and suppress cell growth 
at the concentrations higher than 10 nM. Such dual ef-
fect has been reported earlier for some defensins [16–
18], and beta-defensin-dependent stimulation of cell 
proliferation has been studied in detail by few research 
groups [19–22]. In particular, it has been shown that 
hBD-2,-3,-4 stimulate keratinocyte proliferation, and 
this process requires hBD-dependent phosphorylation 
of EGFR, STAT1 and STAT3 [21]. Another study [23] 
has shown that hBD-2-dependent proliferation of hu-
man conjunctival fibroblasts is mediated by activation 
of p42/44 MAP kinase and Akt. Killing effects of hBDs 
toward cultured human tumor cells have been studied 
in many works, and they are thought to be realized via 
membrane lysis [reviewed in 24].
At the same time the mechanism of action of defen-
sins at concentration range between pro-proliferative 
and cytolytic doses was not analyzed yet, and our 
research is the first one in this field. We have analyzed 
the growth suppressing arm of hBD-2-concentration 
curve, namely its concentrations between 10 and 
1000 nM. These medium concentrations could be con-
sidered close enough to physiologic margins reported 
in some related publications [25, 26].
First of all we have studied effect of nanomolar 
concentrations of rec-hBD-2 on cell cycle distribution 
and signal pathways that regulate G1/S cell cycle transi-
tion. The obtained results have shown that exogenously 
added rec-hBD-2 caused G1/S cell cycle arrest in both 
cell lines via significant dephosphorylation of pRB and 
inhibition of cyclin D1 expression, while p53 expression 
remained unaffected. So, the growth inhibitory action 
of rec-hBD-2 could be in part realized through pRB 
activation, and this fact is of significant importance. 
It is well recognized that the pRB plays a tumor suppres-
sive function and is able to promote cell cycle exit via the 
control of activity of E2F transcription factors regulating 
a number of genes, involved into the G1 to S transi-
tion [27]. As far as we know, it is a first report on a new 
biologic activity of hBD-2 as a native activator of pRB. 
According to the data of immunocytochemical and 
immunocytofluorescent analysis, rec-hBD-2 enters 
the cells, may be found in cytoplasm and also — in cell 
nuclei; the latest fact points on a possibility that this 
defensin may play a role in gene transcription. Accord-
a b
1 2 3 4 1 2 3 4
Fig. 6. RT-PCR analysis of hBD-2 mRNA expresssion 
in А-549 cells (a). The cells А549 (2,5х105 ) were grown 
in 3 cm Petri dishes, cultured for 24 h in serum free medium, and 
then treated with 1,25- (0H)2D3 or (25)(0H)D3 at the concentra-
tions of 40 ng/ml for 12 h. a — 1 — DNA ladder (Fermental, 
Lithuania); 2 — control A549 cells; 3- the cells treated with 40 ng/
ml 1,25-(0H)2D3; 4 — the cells treated with 40 ng/ml 25(0H)D3. 
β-actin is used as a house-keeping gene (b)
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Fig. 7. Immunocytochemical staining of hBD-2 in intact A459 cells 
(a) and the cells treated with the 1000 nM rec-hBD-2 for 48 h (b) 
or 40 ng/ml 1,25-(0H)2D3 for 48 h (c). Magnification x400
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ing to recent data, some antimicrobial peptides were 
found in cancer cell nuclei, in particular, hBD-1 [28] 
and cathelicidine LL-37 [29]. However, biologic role 
of nuclear translocation of these peptides have got 
no explanations so far.
To check if the observed effects of rec-hBD-2 may 
reflect similar physiologic events related to the ac-
tion of native hBD-2 and are not related to artifacts, 
we have analyzed cell growth patterns of A549 cells 
in which hBD-2 mRNA expression is induced by treat-
ment with VD3 metabolites. We have demonstrated 
that VD3-treated A549 cells express hBD-2 mRNA 
and possess lower growth rates than control cells that 
do not express the defensin. It is known that VD3 me-
tabolites regulate more than two hundred genes, 
not only this one; so, we have analyzed if a depletion 
of newly secreted defensin molecules from culture 
medium of 1,25-(0H)2D3-treated cells will restore 
growth rates of these cells. So, in a model experiment 
with A549 cells we have induce hBD-2 expression 
(treatment with 40 ng/ml 1,25-(0H)2D3; 24 h after such 
induction we have added anti-hBD-2 Abs into cell 
culture medium to bind defensin molecules that are 
secreted from the cells; and 48 h after the beginning 
of VD3 treatment we have revealed that anti-hBD-
2-Abs treated hBD-2 expressing A549 cells do not 
differ by cell counts from control A549 cells. So, 
we conclude that growth suppression of A549 cells 
in which hBD-2 expression was induced by VD3 me-
tabolites, is related to action of native defensin. Also, 
we have observed specific hBD-2 immunostaining 
in (1,25)(0H)2D3 treated cells (Fig. 7) and its nuclear 
localization (data not shown). So, one may conclude 
that autocrine effect of native hBD-2 toward A549 cells 
is similar to that of recombinant defensin. 
All these data allowed us to propose a hypothesis 
on a possible mechanism of hBD-2 dual concentra-
tion-dependent action on eucaryotic cells in vitro. 
Let’s remember that this peptide is shown to be involved 
in wound healing in vitro and in vivo stimulating kerati-
nocyte proliferation and migration [10, 21]; at the same 
time this process couldn’t be endless. From other side, 
biophysical studies evidence on an ability of the defensin 
to form oligomers in water solutions [3] — hBD-2 may 
exist in monomeric, dimeric or octameric forms, and the 
latest ones, according to the authors conclusion, are 
responsible for the disruption of bacterial membranes. 
It’s tempting to speculate that the concentration-
dependent mode of influence of hBD-2 could be re-
lated to different mechanisms of action of monomeric 
and oligomeric forms of these molecules — possibly, 
receptor-mediated for monomeric forms (with pro-pro-
liferative mode of action), membrane-penetrating ones 
for dimeric forms (with growth suppressing activity) and 
cytolytic activity characteristic for octamers. However, 
such hypothesis is a speculative one and requires further 
experimental research. 
In conclusion, the data of the present research al-
low to suggest that human beta-defensin-2 may act 
as a native regulator of cell growth — either positive 
at low concentrations or negative at higher ones, and 
further research in this field may help to reveal new 
activities of this peptide antibiotic in epithelial cells.
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